spacer
home > ebr > summer 2018 > calibrating expectations
PUBLICATIONS
European Biopharmaceutical Review

Calibrating Expectations

In Europe and the US, biosimilar drugs are gaining acceptance among physicians, payers, and patients in areas such as kidney disease, growth disorders, cancer, and auto-immune conditions. Progress has been slower in diabetes, but the pandemic nature and heavy cost burdens of the illness may fuel demand for biosimilars in the future. Examining the track record of follow-on biologics in other therapeutic areas can suggest constructive ways to envision the future for diabetes.

By many measures, the global epidemic in diabetes dwarfs other public health challenges. An estimated 60 million Europeans and 30 million Americans have diabetes today. In the US, about 1.5 million people are diagnosed with the disease each year. Many of them patients have transitioned from prediabetes, which affects 84 million Americans. The economic toll is also difficult to ignore.

Direct medical costs linked to diabetes come to about $237 billion a year in the US – more than for any other illness. Insulin and other anti-diabetic drugs, along with treatments for complications, make up 45% of total direct costs.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Rafal Kokolus brings to Syneos Health more than 10 years of combined pharma consulting and drug development/commercialisation experience. He has supported several major pharma and biotech companies in maximising the commercial value of pipeline and in-line assets and optimising marketing and brand strategy. Rafal earned an MBA from University of Western Ontario’s Richard Ivey School of Business, Canada, and a BSc in cell biology and genetics from the University of British Columbia, Canada, and a Graduate Diploma in business administration from Simon Fraser University, Canada.

Dr Doug Niven specialises in pricing and market access at Syneos Health where he has been for the last six years. Prior to this, Doug worked within PwC’s Healthcare Strategy practice. Doug holds a PhD in physics from the University of Birmingham, UK, and a BSc in economics and finance from the University of London, UK.

Rohit Sood leads the global commercial strategy and planning practice at Syneos Health Consulting. During his 12 years at Syneos, he has advised clients in the areas of portfolio planning, commercialisation and launch excellence, and corporate strategy. Rohit has worked with several clients helping them think through their biosimilar go-to-market strategy.
spacer
Rafal Kokolus
spacer
spacer
spacer
Dr Doug Niven
spacer
spacer
spacer
Rohit Sood
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kieran Coulton named new Chairman at ChargePoint Technology

ChargePoint Technology, specialists in contained and sterile powder transfer solutions has announced the appointment of Kieran Coulton as Chairman. Coulton is an accomplished leader in automation and manufacturing with a track record of 36 years in the industry. Having previously served as President Global Industry for GE Power Conversion, Kieran brings with him a wealth of experience and an ability to achieve excellent levels of business growth.
More info >>

White Papers

The Key To Tableting Success: How To Choose The Right Tooling

Natoli Engineering Company, Inc.

Choosing the right tooling can increase tablet output, decrease waste and ultimately determine the success of a product launch.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement